TNIK是肺鳞状细胞癌的治疗靶点并通过Merlin调控FAK活化
肺鳞状细胞癌缺乏获批靶向治疗,3q染色体远端扩增是最常见基因组改变。该研究发现蛋白激酶TNIK在约50%的LSCC病例中扩增,其基因敲低或药理抑制可在体内外减少LSCC细胞生长,并在已建立的LSCC患者来源异种移植瘤中显示抗肿瘤活性并增加凋亡。机制上,研究鉴定肿瘤抑制因子Merlin/NF2为TNIK新底物,TNIK与Merlin为黏着斑激酶活化所必需。
要点
- TNIK在约50%的LSCC病例中扩增,是3q扩增子内可成药靶点。
- TNIK基因敲低或药理抑制在体内外减少LSCC细胞生长。
- TNIK抑制在LSCC患者来源异种移植瘤中显示抗肿瘤活性并增加凋亡。
核心结论
- 靶向TNIK是LSCC的潜在治疗策略。
研究设计与样本
- 临床前研究,采用LSCC细胞系体外实验、体内模型及已建立的LSCC患者来源异种移植瘤。
主要发现
- TNIK在约50%的LSCC病例中扩增。
- TNIK基因敲低或药理抑制减少LSCC细胞体外和体内生长。
- TNIK抑制在已建立的LSCC患者来源异种移植瘤中显示抗肿瘤活性并增加凋亡。
- Merlin/NF2被鉴定为TNIK新底物,TNIK与Merlin为黏着斑激酶活化所必需。
关键数值与推荐
- TNIK在约50%的LSCC病例中扩增。
临床怎么用
- TNIK催化活性对维持LSCC活力至关重要,其抑制在LSCC临床前模型中具有抗肿瘤疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung squamous cell carcinoma (LSCC) is the second most prevalent type of lung cancer. Despite extensive genomic characterization, no targeted therapies are approved for the treatment of LSCC. Distal amplification of the 3q chromosome is the most frequent genomic alteration in LSCC, and there is an urgent need to identify efficacious druggable targets within this amplicon. We identify the protein kinase TNIK as a therapeutic target in LSCC. TNIK is amplified in approximately 50% of LSCC cases. TNIK genetic depletion or pharmacologic inhibition reduces the growth of LSCC cells in vitro and in vivo. In addition, TNIK inhibition showed antitumor activity and increased apoptosis in established LSCC patient-derived xenografts. Mechanistically, we identified the tumor suppressor Merlin/NF2 as a novel TNIK substrate and showed that TNIK and Merlin are required for the activation of focal adhesion kinase. In conclusion, our data identify targeting TNIK as a potential therapeutic strategy in LSCC. SIGNIFICANCE: Targeted therapies have not yet been approved for the treatment of LSCC, due to lack of identification of actionable cancer drivers. We define TNIK catalytic activity as essential for maintaining LSCC viability and validate the antitumor efficacy of TNIK inhibition in preclinical models of LSCC.This article is highlighted in the In This Issue feature, p. 1307.
引用
- Torres-Ayuso P, An E, Nyswaner KM, et al. TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. Cancer Discov. 2021. PMID: 33495197. doi:10.1158/2159-8290.CD-20-0797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。